241 related articles for article (PubMed ID: 7915096)
21. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
[TBL] [Abstract][Full Text] [Related]
22. [Preliminary studies on c-erbB-2 protooncogene in breast cancer].
He LW
Zhonghua Zhong Liu Za Zhi; 1992 May; 14(3):171-4. PubMed ID: 1356719
[TBL] [Abstract][Full Text] [Related]
23. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer.
Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
Surgery; 2003 Feb; 133(2):219-21. PubMed ID: 12605184
[TBL] [Abstract][Full Text] [Related]
25. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
Wright C; Angus B; Nicholson S; Sainsbury JR; Cairns J; Gullick WJ; Kelly P; Harris AL; Horne CH
Cancer Res; 1989 Apr; 49(8):2087-90. PubMed ID: 2564806
[TBL] [Abstract][Full Text] [Related]
26. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
[TBL] [Abstract][Full Text] [Related]
27. [Prognostic significance of expression of c-ERBB-2 oncoprotein in breast cancer patients].
Osaki A; Toi M; Yamada H; Kawami H; Kuroi K; Toge T
Gan To Kagaku Ryoho; 1991 Jun; 18(7):1181-5. PubMed ID: 1675844
[TBL] [Abstract][Full Text] [Related]
28. HER-2/neu amplification predicts poor survival in node-positive breast cancer.
Borg A; Tandon AK; Sigurdsson H; Clark GM; Fernö M; Fuqua SA; Killander D; McGuire WL
Cancer Res; 1990 Jul; 50(14):4332-7. PubMed ID: 1973070
[TBL] [Abstract][Full Text] [Related]
29. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
30. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
[TBL] [Abstract][Full Text] [Related]
31. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
32. Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer.
Kerns BJ; Jordan PA; Huper G; Marks JR; Iglehart JD; Layfied LJ
Mod Pathol; 1993 Nov; 6(6):673-8. PubMed ID: 7905629
[TBL] [Abstract][Full Text] [Related]
33. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
Gaffey MJ; Frierson HF; Williams ME
Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
[TBL] [Abstract][Full Text] [Related]
34. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
35. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.
Berger MS; Locher GW; Saurer S; Gullick WJ; Waterfield MD; Groner B; Hynes NE
Cancer Res; 1988 Mar; 48(5):1238-43. PubMed ID: 2893663
[TBL] [Abstract][Full Text] [Related]
36. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
37. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
Kern JA; Slebos RJ; Top B; Rodenhuis S; Lager D; Robinson RA; Weiner D; Schwartz DA
J Clin Invest; 1994 Feb; 93(2):516-20. PubMed ID: 7906694
[TBL] [Abstract][Full Text] [Related]
38. ERBB2 amplification in breast cancer with a high rate of proliferation.
Borg A; Baldetorp B; Fernö M; Killander D; Olsson H; Sigurdsson H
Oncogene; 1991 Jan; 6(1):137-43. PubMed ID: 1671531
[TBL] [Abstract][Full Text] [Related]
39. [Expression of c-erbB2 protein and its relation to prognosis in 284 primary breast cancer patients].
Yang LF; Song ST; Li XB; Jiang ZF; Liu XQ; Ma WN; Jiao XP; Guo SQ
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):294-7. PubMed ID: 16875632
[TBL] [Abstract][Full Text] [Related]
40. erbB-2 expression in well-differentiated adenocarcinoma of the stomach predicts shorter survival after curative resection.
Motojima K; Furui J; Kohara N; Izawa K; Kanematsu T; Shiku H
Surgery; 1994 Mar; 115(3):349-54. PubMed ID: 7907434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]